Meeting ID: 981 2806 6231 Passcode: 848194 One tap mobile +16468769923,,98128066231# US (New York) +16465189805,,98128066231# US (New York)
Dial by your location +1 646 876 9923 US (New York) +1 646 518 9805 US (New York) Meeting ID: 981 2806 6231 Find your local number: https://meetmsk.zoom.us/u/acLK4eNRzf
Day 2 Course Schedule-March 21, 2023
*Course times (Eastern Standard Time)
Time (EST)
Topic:
Presenter(s):
11:00-12:00pm
Checkpoint Blockade
Dr. Jedd Wolchok
12:00-1:00pm
Translational opportunities in immunotherapy research
Dr. Taha Merghoub
1:00-1:10pm
10 min break
BREAK
1:10-2:05pm
Mentorship Lunch: Finding/funding the right opportunities (small groups)
Dr. Jedd Wolchok Dr. Taha Merghoub Dr. Santosh Vardhana
2:05-2:40pm
Integrating Radiation Oncology into IO Treatment
Dr. Christopher Barker
2:40-2:55pm
2:55-3:50pm
15 min break
Single cell analysis in immunotherapy
BREAK
Dr. Dana Pe'er
3:50-4:50pm
Investigating immunotherapy in underserved populations
Dr. Devika Jutagir
March 2023- Immuno-Oncology for the Translational Researcher Short Course (ITRSC)
About this course
The Memorial Sloan Kettering Cancer Center (MSKCC) Immuno-oncology for the Translational Researcher Short Course (ITRSC) is a cancer education and research experience that will enable eligible junior NCI-funded faculty to learn about tumor immunology, current immunotherapy-based clinical practice and cutting-edge translational research under the mentorship of expert MSKCC faculty. Program participants will attend an intensive 3-day virtual course, led by those centrally involved in basic and clinical immuno-oncology research. ITRSC participants will also have an opportunity to seek additional mentorship and guidance from world experts on immuno-oncology.
The objective of the ITRSC is to engage participants in an in-depth and participatory educational experience covering the topics relevant to clinical immunotherapy research and practice today: checkpoint blockade, novel immunomodulatory antibodies, cellular therapy, immune-monitoring, clinical trial design and development and points of integration with traditional cancer therapy.